Oncology Focus - The company transitioned its strategic focus to oncology following the acquisition of Theriva Biologics in March 2022, developing the oncolytic adenovirus platform for cancer treatment [122]. - The lead product candidate, VCN-01, is currently in a Phase 2b clinical study for pancreatic cancer and has been used in Phase 1 studies for retinoblastoma and other solid tumors [122]. - The VIRAGE Phase 2b trial for metastatic pancreatic cancer involved 112 patients, comparing standard chemotherapy with and without VCN-01 [135]. - Patients receiving VCN-01 + GA showed improved overall survival (OS) of 14.8 months compared to 11.6 months for GA alone, with a hazard ratio (HR) of 0.44 (P=0.046) [136]. - The Phase 2b VIRAGE trial achieved target enrollment of 92 evaluable patients, with 36 patients receiving their second doses of intravenous VCN-01, which were well tolerated [146]. - VCN-01 has been administered to 142 patients across multiple Phase 1 clinical trials and the Phase 2b VIRAGE trial, targeting various cancers including pancreatic cancer and retinoblastoma [142]. - The FDA granted Fast Track Designation to VCN-01 in combination with gemcitabine and nab-paclitaxel to improve progression-free survival and overall survival in patients with metastatic pancreatic adenocarcinoma [149]. - The Independent Data Monitoring Committee found that VCN-01 was well tolerated in combination with standard-of-care chemotherapy, with adverse events consistent with prior clinical trials [153]. - The company received Rare Pediatric Drug Designation for VCN-01 for the treatment of retinoblastoma, which may lead to a Priority Review Voucher if approved by September 30, 2026 [160]. - The European Medicines Agency granted Orphan Medicinal Product Designation to VCN-01 for the treatment of retinoblastoma [161]. - VCN-01 demonstrated enhanced anti-tumor effects in human pancreatic cancer xenograft-bearing mice when combined with liposomal irinotecan [148]. - The Phase 2b trial of VCN-01 in combination with standard-of-care chemotherapy is being conducted at approximately 17 sites in the US and EU [145]. - The company plans to conduct a stand-alone Phase 3 study of VCN-01 with gemcitabine/nab-paclitaxel based on FDA guidance [151]. - The Phase 1 trial of VCN-01 combined with durvalumab enrolled 20 patients, with a median of 4 prior lines of therapy, showing promising results in both concomitant and sequential administration schedules [164]. - In the concomitant schedule, overall survival (OS) was 10.4 months, while in the sequential schedule, OS was 15.5 months at a dose of 3.3×10^12 viral particles (vp) and 17.3 months at 1×10^13 vp [168]. - 66.6% of patients receiving huCART-meso after VCN-01 showed tumor shrinkage, indicating a potential benefit of the combination therapy [167]. - The study of VCN-01 in patients with high-grade brain tumors aims to confirm the presence of the treatment in resected specimens, potentially paving the way for larger trials [170]. - VCN-01 showed sustained blood levels and increased serum hyaluronidase levels for over six weeks, indicating biological activity in patients [168]. - The clinical trial of huCART-meso cells in combination with VCN-01 demonstrated safety consistent with expectations from monotherapy studies [167]. - VCN-01 combined with liposomal irinotecan showed significant tumor growth inhibition in pancreatic cancer models [189][195]. - VCN-11, a next-generation oncolytic adenovirus, exhibited 450 times more cytotoxicity in tumor cells compared to normal cells [191]. Financial Performance - The company implemented a workforce reduction of approximately 32%, or seven employees, to focus resources on business development and clinical trial planning, expecting to save approximately $1.8 million annually [125]. - The company raised approximately $4.4 million from the exercise of existing warrants, with net proceeds expected to be used for working capital [127]. - The company plans to extend its cash runway into the first quarter of 2027 through cost reductions and capital raised from the ATM Sales Agreement [125]. - General and administrative expenses decreased by 18% to $1.9 million for the three months ended September 30, 2025, from $2.3 million for the same period in 2024 [209]. - Research and development expenses decreased by 7% to $2.6 million for the three months ended September 30, 2025, from approximately $2.7 million for the same period in 2024 [210]. - Total research and development expenses for the nine months ended September 30, 2025, were $7.5 million, a decrease of 18% from approximately $9.1 million for the same period in 2024 [217]. - The net loss for the three months ended September 30, 2025, was $4.4 million, or ($0.45) per common share, compared to a net loss of $7.7 million, or ($6.81) per common share for the same period in 2024 [215]. - The net loss attributable to common stockholders for the nine months ended September 30, 2025, was approximately $21.7 million, or ($3.38) per share, compared to a net loss of approximately $21.2 million, or ($24.47) per share for the same period in 2024 [222]. - As of September 30, 2025, the accumulated deficit was $356.7 million, with expectations of continued losses due to reliance on successful phase 3 clinical trials and FDA approvals [223]. - Cash and cash equivalents totaled $7.5 million as of September 30, 2025, a decrease of $4.1 million from December 31, 2024, but increased to $15.5 million in early November 2025 due to net proceeds from sales [224]. - Cash used in operating activities was $13.8 million for the nine months ended September 30, 2025, compared to $12.2 million for the same period in 2024, primarily for the development of VCN-01 [235]. - Cash provided by financing activities for the nine months ended September 30, 2025, included $1.8 million from research and development tax credits and $6.7 million from the sale of Common Stock [237]. - The company has an obligation to pay up to $70.2 million in additional consideration under the VCN Purchase Agreement, with $6.8 million paid to date [229]. - Future clinical trials are expected to require larger cash expenditures, and the company currently lacks committed sources of financing for these trials [227]. - The company anticipates needing additional funding to continue the development of product candidates and to maintain operations beyond early 2027 [232]. - There is substantial doubt about the company's ability to continue as a going concern without additional capital or strategic actions [225]. Research and Development - The company is exploring value creation options for its previous GI disease assets, SYN-004 and SYN-020, including out-licensing or partnering [123]. - The Phase 1b/2a clinical trial of SYN-004 (ribaxamase) aims to evaluate safety and tolerability in up to 36 adult allogeneic hematopoietic cell transplant (HCT) recipients [177]. - Positive outcomes from the Data and Safety Monitoring Committee review allowed the study to proceed to the second cohort, which involves administering SYN-004 with piperacillin/tazobactam [178]. - The SYN-004 program targets prevention of antibiotic-mediated microbiome damage, potentially reducing the incidence of Clostridioides difficile infection (CDI) and acute graft-versus-host disease (aGVHD) [173]. - The company is actively maintaining and building its patent portfolio to support its gastrointestinal and microbiome-focused pipeline [172]. - SYN-004 (ribaxamase) Phase 1b/2a trial safety and pharmacokinetic data presented at major conferences in 2023 [179][180]. - SYN-020 production cost anticipated to be a few hundred dollars per gram, significantly lower than the current market price of $10,000 per gram [182]. - SYN-020 demonstrated a favorable safety profile in Phase 1 studies, with no serious adverse events reported [185]. - The company is exploring strategic opportunities for SYN-004 and SYN-020 assets, including out-licensing or partnerships [188]. - Enrollment for the third cohort of the SYN-004 trial is contingent on obtaining grant funding or finding a partner [180]. - Research and development expenses directly related to VCN-01 were $1.4 million for the three months ended September 30, 2024, compared to $1.37 million for the same period in 2025 [212]. - Total direct research and development costs for the nine months ended September 30, 2025, were $4.89 million, down from $5.77 million for the same period in 2024 [218]. - The fair value of in-process R&D was written down from $19.8 million to $18.6 million, resulting in a $1.3 million impairment charge during the nine months ended September 30, 2024 [220]. - The charge related to stock-based compensation expense was $269,000 for the nine months ended September 30, 2025, compared to $335,000 for the same period in 2024 [216]. - Contingent consideration liabilities increased by $9.2 million due to the achievement of primary survival and safety endpoints in the VIRAGE Phase 2b clinical trial of VCN-01 [216]. - Theriva Biologics holds over 135 U.S. and foreign patents, supporting its various programs [197]. - SYN-004 and SYN-020 programs are backed by strong intellectual property, with patent terms extending to at least 2035 and 2038-2040 respectively [198][199]. - THERICEL program aims to enhance the efficiency and reduce the cost of VCN-01 manufacturing for clinical trials [194]. Corporate Governance - The company filed a prospectus supplement to offer and sell up to $2,534,352 of common stock, with sales made through an at-the-market offering [124]. - The Board approved an amendment to the 2020 Stock Incentive Plan, increasing the number of shares available for grant from 2,500,000 to 4,500,000 [128]. - The company does not recognize Right of Use (ROU) assets or lease liabilities for short-term leases with original terms of 12 months or less [240]. - As of September 30, 2025, the company did not have any material finance leases [240]. - ROU assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term [239].

Financial Performance - Cash and cash equivalents totaled $7.5 million as of September 30, 2025, down from $11.6 million as of December 31, 2024; following a capital raise, cash increased to $15.5 million as of November 10, 2025, extending the cash runway into Q1 2027[1][10] - Other income for Q3 2025 was $79,000, down from $161,000 in Q3 2024, primarily due to a decrease in interest income[9] - Net loss for the three months ended September 30, 2025, was $4,361,000 compared to a net loss of $7,726,000 for the same period in 2024, showing an improvement of about 43%[20] - The company reported a total comprehensive loss of $19,802,000 for the nine months ended September 30, 2025, compared to $21,126,000 in 2024, indicating a decrease of approximately 6%[20] Expenses - General and administrative expenses decreased by 18% to $1.9 million for Q3 2025, down from $2.3 million in Q3 2024, primarily due to reduced compensation costs[7] - Research and development expenses decreased by 7% to $2.6 million for Q3 2025, compared to approximately $2.7 million in Q3 2024, attributed to lower clinical trial expenses related to the completion of the VIRAGE Phase 2b trial[8] - Research and development expenses for the nine months ended September 30, 2025, were $7,472,000, down from $9,145,000 in 2024, a reduction of approximately 18%[20] - General and administrative expenses decreased from $5,702,000 for the nine months ended September 30, 2024, to $14,516,000 in 2025, reflecting a significant increase of about 154%[20] - The company expects a decrease in general and administrative expenses due to a workforce reduction implemented on September 30, 2025[7] Clinical Trials and Research - The VIRAGE Phase 2b trial demonstrated improved overall survival (OS) and progression-free survival (PFS) for metastatic pancreatic ductal adenocarcinoma (PDAC) patients receiving VCN-01 with standard-of-care chemotherapy compared to those receiving chemotherapy alone[6][4] - VCN-01 was administered to 142 patients in various clinical trials, including those for PDAC, with a focus on enhancing tumor immunogenicity and improving chemotherapy access[11] - Preclinical data for VCN-12 showed increased cell killing compared to VCN-01 in various cancer cell models, indicating potential for enhanced therapeutic efficacy[6] - The company plans to discuss a potential Phase 3 clinical trial protocol for VCN-01 with regulators in Europe and the United States in the first half of 2026[2][6] - Additional funding will be required to initiate new VCN-01 clinical trials following the completion of the VIRAGE Phase 2b trial[10] - Additional funding will be required to initiate new VCN-01 clinical trials, highlighting the need for ongoing financial support[15] Assets and Liabilities - Total current assets decreased from $16,281,000 on December 31, 2024, to $9,903,000 on September 30, 2025, a decline of approximately 39%[18] - Cash and cash equivalents dropped from $11,609,000 to $7,528,000, representing a decrease of about 35%[18] - Total liabilities increased from $16,285,000 at the end of 2024 to $24,098,000, marking a rise of approximately 48%[18] Strategic Positioning - The company is positioned to advance its regulatory and clinical strategies and explore potential partnerships for its innovative assets[15] - Current cash funding operations are projected to last into the first quarter of 2027, including overhead costs and the closeout of the VIRAGE Phase 2b clinical trial[15]

Core Insights - Theriva Biologics has made significant progress in its oncology pipeline, particularly with VCN-01 for metastatic pancreatic ductal adenocarcinoma (PDAC) and VCN-12, a next-generation oncolytic virus [2][3] Financial Overview - As of September 30, 2025, cash and cash equivalents were $7.5 million, which increased to $15.5 million following recent capital raises, extending the cash runway into Q1 2027 [8] - General and administrative expenses decreased by 18% to $1.9 million for Q3 2025 compared to $2.3 million in Q3 2024, primarily due to reduced compensation costs [5] - Research and development expenses decreased by 7% to $2.6 million for Q3 2025 from approximately $2.7 million in Q3 2024, attributed to lower clinical trial expenses [6] Clinical Development - Expanded data from the VIRAGE Phase 2b trial showed that VCN-01 combined with standard-of-care chemotherapy improved overall survival (OS) and progression-free survival (PFS) in metastatic PDAC patients [3][12] - The company is pursuing regulatory interactions with the European Medicines Agency and the US FDA for a proposed Phase 3 study of VCN-01 plus gemcitabine/nab-paclitaxel as first-line treatment for metastatic PDAC [2] - VCN-12 demonstrated increased cell killing in preclinical studies compared to VCN-01 and showed a similar toxicity profile in animal studies [9] Pipeline and Future Plans - The company is designing a potential Phase 2/3 clinical trial for retinoblastoma, with discussions with regulators anticipated in the first half of 2026 [2] - Ongoing preclinical studies for VCN-12 are expected to confirm its efficacy and safety profile [9]

Core Insights - Theriva Biologics has reported unusual trading activity in its common stock on October 24, 2025, but does not believe corrective actions are necessary [1] - The company has confirmed that there are no undisclosed material developments affecting its business [1] - On October 13, 2025, Theriva presented expanded data from its VIRAGE trial for VCN-01 at the ESMO 2025 Annual Congress [1] Company Overview - Theriva Biologics is a diversified clinical-stage company focused on developing therapeutics for cancer and related diseases in areas of high unmet need [2] - The company's subsidiary is developing an oncolytic adenovirus platform for intravenous, intravitreal, and antitumoral delivery to enhance tumor cell death and improve the efficacy of cancer therapies [2] - Key clinical-stage candidates include: - VCN-01 (zabilugene almadenorepvec), designed to selectively replicate within tumor cells and degrade the tumor stroma barrier [2] - SYN-004 (ribaxamase), aimed at degrading certain IV beta-lactam antibiotics in the GI tract to prevent microbiome damage and reduce acute graft-versus-host disease [2] - SYN-020, a recombinant oral formulation of intestinal alkaline phosphatase intended for local GI and systemic disease treatment [2]

Core Points - Theriva Biologics has entered into a warrant inducement agreement with existing institutional investors for the immediate exercise of existing warrants to purchase up to 7,360,460 shares of common stock at a reduced exercise price of $0.54 per share, generating approximately $4.0 million in gross cash proceeds [1][2] - In exchange for the immediate exercise of existing warrants, investors will receive new unregistered warrants to purchase up to 14,720,920 shares of common stock, also at an exercise price of $0.54 per share, which will be exercisable upon stockholder approval [2][4] - The closing of the warrant inducement transaction is expected to occur on or about October 17, 2025, subject to customary closing conditions [2][3] Company Overview - Theriva Biologics is a diversified clinical-stage company focused on developing therapeutics for cancer and related diseases, with a particular emphasis on high unmet medical needs [6] - The company's lead clinical-stage candidates include VCN-01, an oncolytic adenovirus targeting tumor cells; SYN-004, designed to protect the gastrointestinal microbiome during antibiotic treatment; and SYN-020, an oral formulation of intestinal alkaline phosphatase for local and systemic diseases [6]

Core Insights - Theriva Biologics is set to present data on its therapeutic candidates VCN-01 and SYN-004 at major upcoming medical conferences, ESMO 2025 and IDWeek 2025, respectively [1][5]. Group 1: VCN-01 - VCN-01 (zabilugene almadenorepvec) is an oncolytic adenovirus that selectively replicates within tumor cells and degrades the tumor stroma, enhancing the efficacy of cancer treatments [3][9]. - The expanded data from the VIRAGE trial, focusing on metastatic pancreatic cancer (mPDAC), will be presented at ESMO 2025 [5][6]. - VCN-01 has been administered to 142 patients across various cancer types, including pancreatic, head and neck, ovarian, colorectal cancers, and retinoblastoma [3][9]. Group 2: SYN-004 - SYN-004 (ribaxamase) is an oral therapy designed to protect the gut microbiome from damage caused by IV beta-lactam antibiotics, thereby preventing Clostridioides difficile infection (CDI) and acute graft-versus-host disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT) recipients [4][8][9]. - Interim blinded safety and pharmacokinetic data from the ongoing Phase 1b/2a trial of SYN-004 will be presented at IDWeek 2025 [5][7]. - A completed Phase 2b clinical trial with 412 patients demonstrated that SYN-004 effectively protected the gut microbiome and reduced the incidence of new colonization by pathogenic microorganisms [8].

Core Insights - Theriva Biologics is advancing its VCN-X discovery program with VCN-12, which shows a novel mechanism of action that may significantly enhance antitumor effects [1][2] - The company will present preclinical data on VCN-01's intracranial administration for brain tumor treatment at the upcoming ESGCT Congress [1][3] Company Overview - Theriva Biologics is a clinical-stage company focused on developing therapeutics for cancer and related diseases, addressing areas with high unmet medical needs [4] - The company's lead candidates include VCN-01, an oncolytic adenovirus designed to selectively replicate within tumor cells and degrade tumor stroma, and SYN-004 and SYN-020, which target gastrointestinal health and systemic diseases [4][5] Product Details - VCN-12 is derived from VCN-01 and is engineered with additional transgenes to improve tumor cell lysis, enhance stroma degradation, and boost the antitumor immune response [2][5] - VCN-01 has been administered to 142 patients across various cancer types, demonstrating its potential in combination with other therapies [6]

Company Updates - Actelis Networks Inc. announced a new contract valued at approximately 5.45% of the company's current market capitalization, resulting in a 43.2% increase in share price to $0.53 in after-hours trading [2] - XCel Brands Inc. reached a settlement agreement and equity transfer deal with the Securities and Exchange Commission, leading to a 66.5% surge in share price to $2.88 in after-hours trading [2] - Rumble Inc. formed a partnership with Perplexity to integrate AI-powered tools, causing shares to rise by 11.4% to $8.23 in after-hours trading [2] - Theriva Biologics Inc. announced plans to reduce its workforce by 32%, which resulted in a 2.1% decline in share price to $0.40 in after-hours trading [2] - Open Text Corp agreed to divest its on-premise solution (eDOCS) from its Analytics portfolio to NetDocuments for $163 million, leading to a 0.8% decrease in share price to $37.36 in after-hours trading [2]

Oncology Development - The company is focused on developing therapeutics for cancer and related diseases, transitioning to oncology after the acquisition of Theriva Biologics in March 2022[126]. - The lead product candidate, VCN-01, has been evaluated in a Phase 2b clinical study for pancreatic cancer, showing a median overall survival (OS) of 14.8 months for patients receiving 2 doses compared to 11.6 months for those receiving standard care alone[140]. - VCN-01 has been administered to 142 patients across multiple Phase 1 and Phase 2b clinical trials, targeting various cancers including pancreatic and retinoblastoma[146]. - The Phase 1 study of VCN-01 in retinoblastoma patients showed promising results, with no systemic toxicities and a well-tolerated profile[138]. - The Phase 2b VIRAGE trial demonstrated that VCN-01 plus standard chemotherapy improved progression-free survival (PFS) to 7.0 months compared to 4.6 months for standard care alone[142]. - VCN-01 has received Orphan Drug Designation and Fast Track Designation from the FDA for the treatment of pancreatic cancer, indicating its potential in addressing unmet medical needs[139]. - The Phase 2b clinical trial VIRAGE for VCN-01 in combination with gemcitabine/nab-paclitaxel began dosing patients in January 2023, targeting newly-diagnosed metastatic pancreatic ductal adenocarcinoma (PDAC) patients[149]. - The Independent Data Monitoring Committee (IDMC) confirmed no safety concerns in the ongoing Phase 2b trial, with VCN-01 demonstrating a safety profile consistent with prior trials[151]. - The FDA granted Fast Track Designation to VCN-01 in combination with gemcitabine and nab-paclitaxel to improve progression-free survival and overall survival in metastatic PDAC patients[153]. - The Phase 1 trial of VCN-01 in combination with durvalumab reported overall survival as 17.3 months for patients receiving the higher dose[166]. - The Phase 1 trial of VCN-01 in combination with huCART-meso cells showed that 66.6% (4 out of 6) patients with measurable disease experienced tumor shrinkage, indicating promising disease stabilization trends[169]. - The ongoing Phase 1 trial of VCN-01 for high-grade brain tumors aims to confirm the presence of VCN-01 in resected surgical specimens, potentially paving the way for larger efficacy trials[171]. - The company is focusing on the development of a next-generation mesothelin-specific CAR-T, potentially in combination with VCN-01 in future trials[170]. - The next-generation oncolytic adenovirus VCN-11 demonstrated 450 times more cytotoxicity in tumor cells compared to normal cells in preclinical studies[192]. Financial Performance - The May 2025 Offering raised approximately $7.5 million through the sale of 1,990,900 shares and warrants, with a combined public offering price of $1.10 per share[129]. - The company has filed a prospectus supplement for the sale of up to 2,534,352 shares of common stock, with a commission rate of up to 3.0% for the sales agent[128]. - General and administrative expenses increased to $11.2 million for Q2 2025, up 662% from $1.5 million in Q2 2024, primarily due to a $9.2 million increase in fair value of contingent consideration related to the VIRAGE Phase 2b clinical trial[209]. - Research and development expenses decreased to $2.0 million for Q2 2025, down 34% from approximately $3.0 million in Q2 2024, attributed to lower clinical trial expenses and manufacturing costs[210]. - The net loss for Q2 2025 was $13.1 million, or ($1.93) per common share, compared to a net loss of $8.3 million, or ($10.72) per common share for Q2 2024[215]. - The accumulated deficit reached $352.4 million as of June 30, 2025, with expectations of continued losses in the foreseeable future[224]. - Cash and cash equivalents totaled $12.1 million as of June 30, 2025, an increase of $0.5 million from December 31, 2024[225]. - The company anticipates needing additional funds for future clinical trials, particularly for larger Phase 3 trials, with no committed sources of financing currently available[226]. - The company raised $6.9 million in net proceeds from a May 2025 offering of 6,818,180 shares of common stock[227]. - As of early August 2025, the company has approximately $9.5 million in cash, which is insufficient to meet its near-term or long-term operational plans[229]. - The net cash used in operating activities for the six months ended June 30, 2025, was $9.5 million, compared to $8.3 million for the same period in 2024, primarily due to the development of VCN-01[232]. - The company expressed substantial doubt about its ability to continue as a going concern without additional capital[229]. - The completion of future Phase 3 and registrational clinical studies will require significant financing or partnerships[230]. Research and Development - The company is exploring value creation options for its previous GI disease assets, SYN-004 and SYN-020, including out-licensing or partnering[127]. - The Phase 1b/2a clinical trial of SYN-004 (ribaxamase) in allogeneic HCT recipients has completed 2 of 3 cohorts, with positive outcomes leading to the recommendation to proceed to the next cohort[182]. - SYN-020 has demonstrated a favorable safety profile in a Phase 1 clinical study, with no serious adverse events reported and mild treatment-related adverse events[186]. - SYN-020 is anticipated to be produced at a cost of a few hundred dollars per gram at commercial scale, significantly lower than the current market price of $10,000 per gram[184]. - The Phase 1 study of SYN-020 included 32 healthy adult volunteers, with positive safety data indicating it was well-tolerated across all dose levels[186]. - Phase 1 data from SAD and MAD studies support the development of SYN-020 for multiple clinical indications, including NAFLD and diseases associated with aging[188]. - The company is exploring strategic opportunities for SYN-004 and SYN-020 assets, including out-licensing or partnerships[189]. - The THERICEL program is advancing a proprietary A549 suspension cell line to support significant scale-up for VCN-01 manufacturing, expected to reduce costs[194]. - The company has over 135 U.S. and foreign patents and over 50 patents pending, supporting its various programs[196]. Regulatory and Compliance - A Type D meeting with the FDA on December 5, 2024, indicated support for a stand-alone Phase 3 study of VCN-01 with gemcitabine/nab-paclitaxel[155]. - The European Medicines Agency (EMA) provided guidance for a potential Phase 3 study of VCN-01, suggesting it could be supported by positive results from a randomized controlled trial[155]. - The FDA granted Rare Pediatric Drug Designation for VCN-01 for retinoblastoma, potentially allowing for a Priority Review Voucher upon approval[161]. - The company entered into an agreement with Massachusetts General Hospital for an exclusive license related to IAP technology, which expired unexercised on July 1, 2024[187]. Goodwill and Liabilities - Goodwill impairment tests are conducted annually, with the last test on October 1, and adjustments made if fair value declines[206]. - Contingent consideration liabilities are measured at estimated fair value at acquisition, with adjustments recorded in the consolidated statements of operations[207]. - Goodwill impairment of $4.0 million was recorded during Q2 2024, reducing the carrying value from $5.5 million to an estimated fair value of $1.5 million[213]. - Other income for Q2 2025 was $74,000, down from $172,000 in Q2 2024, primarily due to a decrease in interest income[214].

Financial Position - Theriva Biologics reported cash and cash equivalents of $12.1 million as of June 30, 2025, with an expected cash runway into Q1 2026[1] - Total assets increased to $35,830 million as of June 30, 2025, compared to $35,352 million at December 31, 2024, reflecting a growth of 1.35%[17] - Current liabilities rose significantly to $12,394 million from $7,585 million, marking an increase of 63.5%[17] - Total stockholders' equity decreased to $10,623 million from $19,067 million, a decline of 44.5%[17] - Accumulated deficit increased to $352,353 million as of June 30, 2025, from $334,971 million at December 31, 2024, indicating a rise of 5.5%[17] Expenses - General and administrative expenses increased by 662% to $11.2 million for Q2 2025, primarily due to a $9.2 million increase in fair value of contingent consideration related to the VIRAGE Phase 2b trial[5] - Research and development expenses decreased by 34% to $2.0 million for Q2 2025, attributed to lower clinical trial expenses for the VIRAGE trial and decreased manufacturing costs[6] - The charge related to stock-based compensation expense was $97,000 for Q2 2025, compared to $114,000 for Q2 2024[5] - Other income for Q2 2025 was $74,000, down from $172,000 in Q2 2024, primarily due to a decrease in interest income[7] - Research and development expenses decreased to $1,953 million in Q2 2025 from $2,953 million in Q2 2024, a reduction of 33.8%[19] - Total operating costs and expenses for the six months ended June 30, 2025, were $17,549 million, up from $13,881 million in the same period of 2024, an increase of 26.3%[19] Net Loss - Net loss for the three months ended June 30, 2025, was $13,058 million, compared to a net loss of $8,316 million for the same period in 2024, representing a year-over-year increase of 57.5%[19] - The company reported a net loss per share of $1.93 for Q2 2025, compared to a net loss per share of $10.72 in Q2 2024[19] - Total comprehensive loss for the six months ended June 30, 2025, was $15,411 million, compared to $14,222 million for the same period in 2024, reflecting an increase of 8.4%[19] Clinical Trials and Research - Positive topline results from the VIRAGE Phase 2b trial indicated increased overall survival, progression-free survival, and duration of response for metastatic pancreatic cancer patients treated with VCN-01 compared to standard chemotherapy[3] - The company is preparing a study protocol for a potential Phase 3 clinical trial for VCN-01 in metastatic pancreatic ductal adenocarcinoma (PDAC)[2] - Expanded data from the VIRAGE trial is scheduled to be presented at the ESMO 2025 Congress on October 20, 2025[3] - Theriva anticipates an increase in research and development expenses as it completes the VIRAGE trial and plans for the potential Phase 3 trial of VCN-01[6] - VCN-01 has been administered to 142 patients in clinical trials across various cancers, demonstrating its potential in treating multiple tumor types[9] Foreign Currency Exchange - The company experienced a foreign currency exchange gain of $20 million in Q2 2025, compared to a loss of $1 million in Q2 2024[19]